Zhuo‐Xun Wu

St. John's University — United States

Medicine · Health Sciences

29h-index5.1kcitations63works6.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(37), HIV/AIDS drug development and treatment(16), Cancer therapeutics and mechanisms(14), Pharmacological Effects and Toxicity Studies(8), Epigenetics and DNA Methylation(5)

Publications63 total

Skin-Temperature-Responsive In Situ Hydrogel for Enhanced EMG Recording of Lumbar Muscle
2025
Correction: Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)
Frontiers in Pharmacology·2025Open Access
Understanding and overcoming multidrug resistance in cancer
Nature Reviews Clinical Oncology·2025· 27 cited
Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)
Frontiers in Pharmacology·2025· 2 citedOpen Access
Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies
Cancer Letters·2024· 10 cited
Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells
Frontiers in Pharmacology·2024· 7 citedOpen Access
Abstract 7193: ABCB1-mediated chemotherapeutic drug resistance is reversed by a potent p53-MDM2 inhibitor NVP-HDM201
Cancer Research·2024
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor
Drug Resistance Updates·2023· 21 cited
Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors
Bioorganic Chemistry·2023· 8 cited
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Signal Transduction and Targeted Therapy·2023· 196 citedOpen Access
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
MedComm·2022· 121 citedOpen Access
Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study
Frontiers in Oncology·2022· 7 citedOpen Access
Abstract 407: OTS964, a TOPK inhibitor, is susceptible to ABCG2-mediated drug resistance
Cancer Research·2022
Abstract 409: Reversal of ABCG2-mediated multidrug resistance by tepotinib <i>in vitro</i> and <i>in vivo</i>
Cancer Research·2022
Quercetin ameliorates oxidative stress‑induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats
Biomedicine & Pharmacotherapy·2022· 32 citedOpen Access
Microbiota in health and diseases
Signal Transduction and Targeted Therapy·2022· 2.7k citedOpen Access
The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells
Frontiers in Oncology·2022· 10 citedOpen Access
Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges
Frontiers in Oncology·2022· 150 citedOpen Access
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
Molecular Cancer·2022· 132 citedOpen Access
The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
Frontiers in Pharmacology·2022· 19 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Zhe‐Sheng Chen(47), Jing‐Quan Wang(27), Yuqi Yang(26), Qiu‐Xu Teng(22), Zi‐Ning Lei(19), Dong‐Hua Yang(11), Chao‐Yun Cai(8), Leli Zeng(6), Qingbin Cui(6), Xuan-Yu Chen(5), Suresh V. Ambudkar(5), Charles R. Ashby(5), Liuya Wei(4), Zhenduo Shi(4), Conghui Han(4), Chang Zou(4), Sabrina Lusvarghi(4), Ning Ji(4), Silpa Narayanan(4), Sabesan Yoganathan(4)